1 Title

4

9

10

- 2 A multicentre point prevalence survey of patterns and quality of antibiotic prescribing in
- 3 Indonesian hospitals
- 5 Authors
- Ralalicia Limato<sup>1,2</sup>, Erni J. Nelwan<sup>3,4,5,6</sup>, Manzilina Mudia<sup>1</sup>, Justin de Brabander<sup>1</sup>, Helio Guterres<sup>3,4</sup>,
- 7 Enty Enty<sup>7,8</sup>, Ifael Y. Mauleti<sup>9</sup>, Maria Mayasari<sup>10</sup>, Iman Firmansyah<sup>11</sup>, May Hizrani<sup>6</sup>, Raph L.
- 8 Hamers<sup>1,2,4</sup>

#### Affiliations and addresses

- 1. Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia (Jl. Diponegoro No.69, Jakarta
- 12 Pusat, DKI Jakarta, Indonesia 10430)
- 2. Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, university of
- 14 Oxford, Oxford, UK (Old Road Campus, Roosevelt Drive, Oxford, OX3 7LG, UK)
- Department of Internal Medicine, Division of Infectious Diseases, Cipto Mangunkusumo
- 16 National General Hospital, Jakarta, Indonesia (Jl. Pangeran Diponegoro No.71, Jakarta Pusat,
- 17 DKI Jakarta, Indonesia 10430)
- 18 4. Faculty of Medicine, University of Indonesia, Jakarta, Indonesia (Jl. Salemba Raya No. 6,
- 19 Jakarta Pusat, DKI Jakarta, Indonesia 10430)
- 20 5. Infectious Disease and Immunology Research Cluster, Indonesian Medical Education and
- 21 Research Institute, Jakarta, Indonesia (Jl. Salemba Raya No.6, Jakarta Pusat, DKI Jakarta,
- 22 Indonesia 10430)
- 23 6. Metropolitan Medical Centre Hospital, Jakarta, Indonesia (Jl. H. R. Rasuna Said No.1, Jakarta
- 24 Selatan, DKI Jakarta, Indonesia 12940)
- 25 7. Royal Taruma Hospital, Jakarta, Indonesia (Jl. Daan Mogot No.34, Jakarta Barat, DKI Jakarta,
- 26 Indonesia 11470)
- Faculty of Medicine and Health Sciences, Atma Jaya Catholic University, Jakarta, Indonesia
- (JI. Pluit Selatan Raya No.19, Jakarta Utara, DKI Jakarta, Indonesia 14440)
- Fatmawati General Hospital, Jakarta, Indonesia (Jl. RS. Fatmawati Raya No.4, Cilandak Barat,
- Jakarta Selatan, DKI Jakarta, Indonesia 12430)
- 10. St. Carolus Hospital, Jakarta, Indonesia (Jl. Salemba Raya No. 41, Jakarta Pusat, DKI Jakarta,
- 32 Indonesia 10440)

- 11. Prof. Dr. Sulianti Saroso Infectious Disease Hospital, Jakarta, Indonesia (Jl. Sunter Permai
- Raya, Jakarta Utara, DKI Jakarta, Indonesia 14340)
- 36 **Short running title:** antibiotic use in Indonesian hospitals
- 37 **Inserts:** 4 tables; 3 figures
- 38 Data supplement: 10 tables

# Corresponding author

40 Raph L. Hamers MD PhD

Address: EOCRU, Jl. Diponegoro No.69, Jakarta Pusat, DKI Jakarta, Indonesia 10430

42 Email: raph.hamers@ndm.ox.ac.uk

43 Phone: +62 21 31900971

44 Fax :-

Synopsis

45 46

47

## Background

- Antibiotic misuse and overuse are a major driver of antimicrobial resistance, but systematic data in
- 49 Indonesia are scarce.
- 50 Objectives
- To evaluate patterns and quality indicators of antibiotic prescribing in six acute-care hospitals in
- 52 Jakarta, Indonesia.
- 53 Methods
- We conducted a hospital-wide point prevalence survey (PPS) between March and August 2019,
- using Global-PPS and WHO-PPS protocols. The analysis focused on antibacterials for systemic
- 56 use (antibiotics).
- 57 **Results**
- 58 Of 1602 inpatients, 993 (62.0%) received ≥1 antimicrobials. Of 1666 antimicrobial prescriptions,
- 59 1273 (76.4%) were antibiotics. Most common reasons for prescribing were pneumonia (27.7%),
- skin and soft tissue infections (8.3%), gastrointestinal prophylaxis (7.9%), and gastrointestinal
- infections (5.4%). The most common indication was community-acquired infection (42.6%),
- followed by surgical prophylaxis (22.6%), hospital-acquired infection (18.5%), medical prophylaxis
- 63 (9.6%), unknown (4.6%) and other indications (2.1%). The most prescribed antibiotic classes were
- third-generation cephalosporins (44.3%), fluoroguinolones (13.5%), carbapenems (7.4%),
- 65 penicillins with B-lactamase inhibitor (6.8%) and aminoglycosides (6.0%). According to the WHO
- 66 AWaRe classification, Watch antibiotics accounted for 67.4%, followed by 28.0% Access, 2.4%
- 67 Reserve, and 2.2% Unclassified. Reason for prescribing, stop/review date and planned duration
- 68 were poorly documented. Hospital antibiotic guidelines were not available for 28.1% of
- 69 prescriptions, and guideline compliance was 52.2% (478/915). Parenteral administration was high
- 70 (85.1%). Targeted (non-empirical) prescriptions comprised 8.1% (44/542) for community-acquired
- 71 infections and 26.8% (63/235) for hospital-acquired infections.
- 72 Conclusions
- 73 Our data indicate a high rate of parenteral, empiric use of broad-spectrum antibiotics in Indonesian
- 74 hospitals, coupled with poor documentation and guideline adherence. The findings suggest
- 75 important areas for antimicrobial stewardship interventions.
  - Key words

- 78 Antimicrobial resistance; antibiotic use; point prevalence survey; antibiotic stewardship; quality
- 79 indicators; WHO AWaRe; Indonesia

83

84

85

86

87

88 89 90

91

92

93

94

95 96

97

98 99

100

101102

103

104105

106

Introduction Drug-resistant infections have been estimated to account for 700,000 deaths per year globally, cumulating to 10 million by 2050, higher than cancer (8.2 million) or diabetes (1.5 million) combined.1 The overuse and misuse of antimicrobial agents has been well-recognised as one of the key drivers of emerging antimicrobial resistance (AMR), <sup>2,3</sup> with antimicrobial consumption projected to rise further globally. In response to the emerging public health crisis of AMR, the World Health Organisation (WHO) has launched a global action plan, including strategies for surveillance and mitigation of antimicrobial overuse.<sup>5</sup> Indonesia, a populous (271 million) and diverse middle-income country, is potentially an AMR hotspot, due to high infectious disease burdens, liberal antibiotic practices, and fragile health systems.<sup>6,7</sup> The Indonesian government is increasingly supporting antimicrobial stewardship (AMS), through the national action plan on AMR launched in 2014<sup>8,9</sup>, and as part of hospital accreditation. 10 However, inappropriate or unnecessary antibiotic prescribing is believed to be widespread, although systematic data are lacking to adequately inform AMS policies. In global datasets reporting point prevalence surveys (PPS) of antibiotic use in hospitals 11-12, low and middle-income countries (LMIC) remain underrepresented to date. 13,14 The recently introduced WHO AWaRe (Access, Watch, Reserve) antibiotic classification framework, based on accessibility versus AMR potential, is a useful metric to provide an indication of the appropriateness of antibiotic consumption. 15,16 We here report the results of a hospital-wide PPS that evaluated patterns and quality indicators of antibiotic use in six acute-care, general hospitals in Jakarta, the capital city of Indonesia, for community and hospital acquired infections and medical and surgical prophylaxis, by hospital, ward type, indication and diagnosis.

**Patients and Methods** 

107

108 109 Study design and population We conducted a hospital-wide PPS of antimicrobial use in a purposive sample of six hospitals 110 across Jakarta, between March and August 2019. We followed Global PPS (2018)<sup>17</sup> and WHO 111 (2019)<sup>11</sup> protocols. Briefly, PPS is a "snap-shot" survey to collate medical record data on 112 113 antimicrobial prescriptions in hospitalized patients. Eligible patients were all hospitalised patients 114 who received ≥1 active antimicrobial by 8 a.m. on the survey day or surgical prophylaxis ≤24 hours 115 prior to the survey. We excluded emergency and day-care wards, outpatient clinics, inpatients who 116 were discharged before or admitted after 8 a.m. 117 The study was approved by the Research Ethics Committee of the Faculty of Medicine of the 118 University of Indonesia (1364/UN2.F1/ETIK/2018) and the Oxford Tropical Research Ethics 119 120 Committee (559-18). The requirement for individual patient consent was waived. Permission was 121 obtained from the hospital management or research/medical committee in each participating 122 hospital. 123 124 Data collection 125 Data collection was conducted by 1 or 2 medical doctors from the study team, joined by 1 to 4 126 hospital staff, who received a one-day training and a data collection form (DCF) completion 127 quideline. Each ward was completely surveyed within one day (to minimise the effect of patient 128 movements) and all wards of a single hospital were surveyed within 4 weeks. If crucial patient data 129 was missing, the responsible nurse or clinician was asked for clarifications. A senior team member 130 (RL, RLH) was available to discuss any data queries and take a final decision. We developed a paper DCF comprising ward, patient and treatment sections, modified from Global-PPS<sup>17</sup> and 131 132 WHO-PPS.<sup>11</sup> De-identified data were checked and entered into a study database. 133 We included systemic antimicrobials coded on the basis of the WHO Anatomical Therapeutic 134 Chemical (ATC) classification system as follows: antibacterials (J01), antimycotics (J02), 135 antifungals (D01BA), antimycobacterials (J04), antivirals (J05), nitroimidazole derivatives (P01AB), 136 intestinal antiinfectives (A07A), and antimalarials (P01B). We recorded the diagnosis/reason for 137 the prescribed antimicrobial (what the clinician aimed at treating or preventing), according to a diagnostic code list<sup>17</sup>. Antimicrobial indications were classified as: 1) community-acquired infection 138 139 (CAI) if symptoms were present on admission or started <48 hours after admission; 2) hospital-140 acquired infection (HAI) if symptoms started ≥48 hours after admission; 3) medical prophylaxis; 4) 141 surgical prophylaxis, categorised as single-dose, one-day, or longer than one day; 5) other; 6) 142 unknown. We recorded the following five quality indicators of prescribing: 1) documentation of diagnosis/reason for antimicrobial use, stop/review date, and treatment duration; 2) hospital 143 144

antibiotic guideline availability and compliance with regards to drug choice (if not available, this

147

148149

150

151

152153

154

155156

157158159

160

161

162163

164

165

166 167

168

169

170

171172

173

174

175176

177178

179

180

181

182

item was recorded as "not assessable"); 3) parenteral administration; 4) culture sample taken in therapeutic use; 5) targeted (antibiotic prescribed in response to microbiology results) or empirical treatment. Statistical analysis We used descriptive statistics to summarise the data, expressed as counts or percentages, by hospital, ward type, indication and diagnosis. The analysis focused on antibacterials for systemic use (ATC code J01) (aka "antibiotics"). Antibiotics were reported by drug names, chemical class (according to the 4th level WHO ATC classification) and AWaRe groups. We used RStudio Version 1.3.1093 for all analyses. Results **Hospital characteristics** Hospitals were tertiary (2) or secondary-level (4), government or private (3 each), including one specializing in infectious diseases (**Table 1**). All hospitals had an antibiotic stewardship team, five hospitals had local antibiotic guidelines, and four hospitals were included in the national health insurance scheme. All 238 inpatient wards across the six hospitals were surveyed, including 87 medical, 31 surgical, 95 mixed medical-surgical wards and 25 intensive care units, of which 123 adult, 51 paediatric-neonatal and 64 mixed adult-paediatric-neonatal. On the survey day, a total of 2358 active hospital beds (median 230, range 134-853 per hospital) accounted for 1602 (67.9%) admitted patients (median 149, range 51-625 per hospital), of whom 993 (62.0%) received ≥1 antimicrobials (median 91, range 33-368 per hospital). The proportion of patients receiving one or more antimicrobials ranged from 53.5% to 78.8% across hospitals (Table 1 and S1). Characteristics of patients receiving one or more antimicrobials Table 2 summarizes patient characteristics. Of 993 patients, 497 (50.1%) were women and 782 (78.8%) were adults, and the median age was 43 years (IQR 22-58.5; range 1 day to 99 years). One or more comorbidities were documented in 48.9% (486) of patients. 368 (37.1%) had undergone surgery and 299 (30.1%) had been hospitalised in the last 90 days, and 145 (14.6%) had been transferred from another hospital. The 993 patients receiving one or more antimicrobials accounted for a total of 1666 active antimicrobial prescriptions (median 1 per patient, range 1-12), with 60.6% (602) receiving one antimicrobial agent, 25.6% (254) two, and 13.8% (137) three or more. Antimicrobial use was highest in ICU (86.8%, 132/152), followed by surgical wards (66.0%, 184/293), mixed medicalsurgical wards (65.0%, 401/622) and medical wards (51.4%, 310/569) (Table S1). Concomitant

use of ≥2 antimicrobials was more frequent in ICU (59.1%, 58/98) than non-ICU (37.2%, 333/895) 183 184 (Table 2). 185 186 Antimicrobial agents prescribed Of all 1666 antimicrobial prescriptions, 76.4% (1273) were antibacterials, followed by 11.4% (197) 187 antimycobacterials, 4.3% (72) antivirals, 3.7% (62) antimycotics, 2.6% (43) intestinal antiinfectives, 188 0.8% (13) antimalarials, and 0.4% (6) nitroimidazole derivatives. The 1273 prescribed antibiotics 189 190 (J01) included 46 different agents. The five most prescribed antibiotics were ceftriaxone (26.8%, 191 341), levofloxacin (10.7%, 137), metronidazole (7.1%, 91), meropenem (6.4%, 82) and cefotaxime (5.6%, 71) –accounting for 56.5% (720) of prescriptions (**Table S2**). The five most prescribed 192 193 antibiotic classes were third-generation cephalosporins (44.3%, 565), fluoroquinolones (13.5%, 172), carbapenems (7.4%, 94), penicillins with B-lactamase inhibitor (6.8%, 86) and 194 aminoglycosides (6.0%, 76) (Figure 1) –accounting for 78.0% (993) of prescriptions. 195 196 197 Reasons for antibiotic prescribing 198 The full list of diagnosis/reasons for all 1666 antimicrobial prescriptions is included in the data 199 supplement (Table S3). Among all 1273 antibiotic prescriptions (J01), the most common diagnosis/reasons were pneumonia (27.7%, 353), skin and soft tissue infections (8.3%, 106), 200 201 gastrointestinal prophylaxis (7.9%, 101), and gastrointestinal infections (5.4%, 69) –accounting for 202 49.4% (629) of all prescriptions (Table 3 and S4). Ceftriaxone and levofloxacin were mainly used 203 to treat pneumonia and gastrointestinal infections. Metronidazole was mainly used for skin and soft 204 tissue infections and intra-abdominal infections, and for gastrointestinal prophylaxis. Meropenem 205 was mainly used for pneumonia and sepsis. Cefotaxime was mainly used for pneumonia and for 206 gastrointestinal prophylaxis. 207 208 Indications for antibiotic prescribing 209 Among all 1273 antibiotic prescriptions (J01), the most common indication was CAI (42.6%, 542), 210 followed by surgical prophylaxis (22.6%, 288), HAI (18.5%, 235), medical prophylaxis (9.6%, 122), unknown (4.6%, 59), and other (2.1%, 27) (**Table S5**) 211 212 213 Among CAI (542), the top-5 diagnosis/reasons were pneumonia (42.6%, 231), skin and soft tissue 214 infection (14.2%, 77), gastrointestinal infection (12.2%, 66), sepsis (5.5%, 30), and intra-abdominal 215 infection (5.4%, 29) (Table S4). The five most common antibiotics for CAI were ceftriaxone (32.8%, 178), levofloxacin (13.5%, 73), metronidazole (8.1%, 44), meropenem (7.7%, 42), and 216 217 ampicillin sulbactam (5.4%, 29) –accounting for 67.5% (366) of prescriptions (**Table S6**). 218 219 The most common HAI was hospital-acquired pneumonia (including other HAI) (70.2%, 165),

followed by intervention-related infections (including catheter-related blood stream infection,

- ventilator-associated pneumonia, catheter-related urinary tract infection) (19%, 35), post-operative
- surgical site infection (13.6%, 32), infection present on admission from another hospital (0.85%, 2)
- or long-term care facility (0.4%, 1); no C. difficile-associated diarrhoea (HAI3) was documented
- (Table S7). The six most common antibiotics for HAI were levofloxacin (18.7%, 44), meropenem
- 225 (13.6%, 32), ceftriaxone (9.8%, 23), amikacin (6.4%, 15), metronidazole and ceftazidime (6%, 14
- each) –accounting for 60.4% (142) of prescriptions (**Table S6**).
- Among medical prophylaxis (122), the top-5 diagnosis/reasons were neonatal (20.5%, 25), general
- 229 (19.7%, 24), gastrointestinal (17.2%, 21), respiratory (15.6%, 19), and unknown (8.2%, 10) (**Table**
- 230 **S4**). The five most common antibiotics for medical prophylaxis were ceftriaxone (28.7%, 35),
- 231 cotrimoxazole (17.2%, 21), gentamicin (10.7%, 13), cefotaxime (8.2%, 10), ampicillin (7.4%, 9) –
- accounting for 72.1% (88) of prescriptions (**Table S6**).

233

241242

252

257

- Among surgical prophylaxis (288), the top-5 diagnosis/reasons were gastrointestinal (27.8%, 80),
- obstetrics/gynaecology (20.1%, 58), bone and joint (17%, 49), urinary tract (12.8%, 37), central
- 236 nervous system and ear-nose-throat (7.3%, 21 each). The most common antibiotics for surgical
- 237 prophylaxis were ceftriaxone (26.4%, 76), cefixime (11.5%, 33), cefoperazone (11.1%, 32),
- metronidazole (9.7%, 28), cefazolin (6.2%, 18) –accounting for 64.9% (187) of prescriptions.
- Notably, duration of surgical prophylaxis was longer than one day for 76% (219) of prescriptions,
- 240 whereas 15.0% (43) was single-dose and 9.0% (26) was for one day.

## Antibiotic use based on AWaRe groups

- Figure 2 summarizes AWaRe groups. Of all 1273 antibiotic prescriptions (J01), 67.4% (858) were
- 244 Watch antibiotics, followed by 28.0% (356) Access, 2.4% (31) Reserve, and 2.2% (28)
- 245 Unclassified. This pattern was similar across indications and ward types. Of note, Watch
- antibiotics were commonly prescribed for the most frequent diagnosis, i.e. pneumonia (34.4%,
- 247 295), gastrointestinal infection (6.6%, 57), and skin and soft tissue infection (5.8%, 50). Watch
- antibiotics (858) comprised 45.1% (387) of CAI, 20.9% (179) of surgical prophylaxis, 19.5% (167)
- of HAI, and 7.2% (62) of medical prophylaxis. The five most used Watch antibiotics were
- 250 ceftriaxone (39.7%, 341), levofloxacin (15.8%, 136), meropenem (9.6%, 82), cefotaxime (8.3%,
- 251 71), and cefoperazone (6%, 52) (**Table S7**).
- Access antibiotics (356) comprised 37.6% (134) of CAI, 27% (96) of surgical prophylaxis, 15.4%
- 254 (55) of medical prophylaxis, and 13.8% (49) of HAI. The five most used Access antibiotics were
- 255 metronidazole (25.3%, 90), ampicillin-sulbactam (12.4%, 44), gentamicin (11.8%, 42), amikacin
- 256 (9%, 32) and amoxicillin-clavulanic acid (8.7%, 31) (**Table S7**, **Figure 3**).

258 Reserve antibiotics were uncommon (31), and included fosfomycin (15, 48.4%), tigecycline (13, 259 41.9%), colistin (1, 3.2%), and linezolid (1, 3.2%). 260 261 Quality indicators of antibiotic use (J01) 262 Documentation of antibiotic plan Reason for prescribing was documented for 63.5% (808/1273) 263 of all prescriptions, with substantial variation between hospitals, indications and ward types (Table 264 4 and S9). Documentation of diagnosis/reason was better for therapeutic use (546/777, 70.3%) than prophylactic use (230/410, 56.0%), and in ICU (75.6%, 118/156) than non-ICU (61.8%, 265 266 690/1117). Stop/review date (15.2%, 194/1273) and planned treatment duration (9.8%, 125/1273) 267 was poorly documented overall, across indications and ward types (Table 4 and S9). 268 Hospital guideline availability and compliance Local antibiotic guidelines were not available for 269 270 28.1% (358/1273) of antibiotic prescriptions; and, of note, for 76.2% (93/122) of prescriptions for 271 medical prophylaxis. Guideline compliance was 52.2% (478/915) overall, 44.8% (223/498) for 272 empirical CAI treatment, 45.9% (79/172) for empirical HAI treatment, 28.5% (82/288) for surgical prophylaxis and 18.9% (23/122) for medical prophylaxis (Table 4). Guideline compliance was 273 274 similar across ward types (Table S9). 275 276 Parenteral use 85.1% (1084/1273) of prescriptions were parenterally administered, including 88.5% (208/235) for HAI, 89.5%% (486/542) for CAI, 75.4% (92/122) for medical prophylaxis and 277 278 82.3% (237/288) for surgical prophylaxis (Table 4). Parenteral use was higher in ICU (97.4%, 279 152/156) than non-ICU (83.4%, 932/1117) (**Table S9**). 280 281 Culture samples taken Among 619 patients with ≥1 antibiotic for therapeutic use, 48.8% (302) had one or more samples taken for bacterial culture (total 831 samples, median 2, range 1-25 per 282 283 patient). Among the top-5 diagnosis/reasons for prescribing, one or more culture sample were 284 taken in 44.8% (154/353) of pneumonias, 51.9% (55/106) of skin and soft tissue infections, 66.7% 285 (38/57) of intra-abdominal infections, 52.2% (24/46) of sepsis, and 75.9% (22/29) of upper UTI. 286 Blood cultures were taken in 44.4% (88/353) of pneumonias, 45.6% (26/57) of intra-abdominal 287 infections, 58.6% (17/29) of upper UTI, and 95.8% (23/24) of sepsis. Sputum cultures were taken 288 in 26.9% (95/353) of pneumonias. Urine cultures were taken in 72.4% (21/29) of upper UTI (Table 289 **S10**). 290 291 Targeted antibiotic treatment Treatment was targeted in 8.1% (44/542) of CAI and 26.8% 292 (63/235) of HAI (Table 4); 13.0% (46/353) of pneumonias, 15.8% (9/57) of intra-abdominal 293 infections, 44.8% (13/29) of upper UTI, and 13% (6/46) of sepsis. Targeted treatment was more

common in ICU (19.9%, 31/156) than in non-ICU (6.8%, 76/1117) (Table S9).

Discussion

295

296

297

298299

300

301

302

303

304

305 306

307 308

309

310

311

312

313

314

315316

317

318

319320

321

322323

324

325

326

327328329

330

331

This was the first contemporary hospital-wide survey in Indonesia that systematically evaluated patterns and quality of antibiotic prescribing, using the recommended PPS methodology. 11,17 We demonstrated the feasibility of PPS in this low-resource setting, and generated useful data to guide local AMS programmes. Our survey found a high proportion (62%) of antimicrobial use among hospitalized patients, ranging from 53.5% to 78.8% across hospitals in Jakarta, with the highest use in ICU (86.8%) as expected. Antibiotic use was substantially higher than reported in global PPS datasets, which were dominated by data from high-income countries in Europe, North America and Asia 13,14 and which highlighted that antimicrobial use was significantly higher in non-European hospitals compared with European hospitals.<sup>14</sup> Consistent with other surveys in Asia 18,19 and globally 13, the predominant reason for antibiotic prescription in Jakarta hospitals were lower respiratory tract infections. In our survey, the mostly used antibiotic classes were third-generation cephalosporines (mainly ceftriaxone), fluoroguinolones (mainly levofloxacin), and carbapenems (mainly meropenem), all predominantly used for pneumonia, among several other diagnosis. Ceftriaxone was the most used antibiotic across all major indications (i.e. CAI, HAI, surgical and medical prophylaxis). These findings are consistent with the widespread use of broad-spectrum antibiotics, predominantly third-generation cephalosporins and fluoroquinolones, in Indonesia<sup>20</sup>, other Asian countries<sup>18,19,21–23</sup> and globally<sup>13,14</sup>, which may suggest that at least a proportion of these prescriptions are unnecessary or inappropriate. Moreover, the empirical use of meropenem for CAI and HAI represented nearly 10% of all antibiotics for therapeutic use. This could partially be explained by high rates of AMR, particularly in common Gram-negative organisms, in Indonesian hospitals.<sup>24</sup> However, targeted prescribing for CAI (8%) and HAI (27%) was low in comparison to a global study (12-27% and 20-44%, respectively)<sup>13</sup>, suggesting underutilization of microbiological diagnostics as well as overuse of broad-spectrum antibiotics. Antibiotic prescriptions for HAI (18.5% of total), predominantly for pneumonia but also interventionrelated and post-operative surgical site infections, were comparable to recent surveys in India (19%)<sup>19</sup> and Thailand (34%)<sup>18</sup>, but considerably higher than in reports from high-income settings. e.g. ECDC survey (6%)<sup>25</sup> and the GLOBAL-PPS survey (8.4%).<sup>13</sup> These data confirm the significantly higher burden of HAI in LMIC compared to high-income countries. A high proportion of antibiotic prescriptions were for surgical (23%) and medical prophylaxis (10%), for a range of indications. Prophylactic prescribing was unusually high for gastrointestinal infections. Prolonged (>1 day) surgical prophylaxis was very common (76%) in our survey, as has

333334

335336

337

338

339

340

341342

343

344

345

346

347

348349350

351

352

353

354

355

356

357

358

359

360 361

362

363

364 365

366

367

368 369

also been observed in other countries in Asia (Pakistan 97%<sup>21</sup>, India 77%<sup>19</sup>, Thailand 90%<sup>18</sup>) as well as in Europe<sup>13,25</sup>. Prolonged antibiotic prophylaxis for more than 24h for most surgical indications does not prevent development of postoperative infections, compared with <24h, but increases the risk of AMR and side-effects. <sup>26</sup> Further research is warranted to explain the reasons for these patterns. We investigated five basic quality indicators, which could be used to set benchmarks for quality improvement of antibiotic use<sup>27</sup> and AMS programmes.<sup>28</sup> Documentation of the reason of prescribing (64%) was lower than reported across studies in Europe, Asia, Africa, and America (70-85%). 13,29 Stop or review date was poorly documented (15%) across indications and ward types. Post-prescription review of a prescribed antimicrobial within 48-72h of the initial order. ensures appropriate choice and route of administration, optimal de-escalation (IV-oral switch) practices, and prevents unnecessarily long antibiotic courses. The high (85%) proportion of parenteral route of administration, coupled with high rates of empirical therapy and suboptimal use of microbiological cultures, suggests lack of de-escalation protocols in the participating hospitals. Pro-active IV to oral switching policies can reduce catheter-related complications, health-care costs, and duration of hospital stays, and is recognized as a key metric for AMS processes 30. Hospital guidelines were not available for 28% of antibiotic prescriptions, including for 76% of prescriptions for medical prophylaxis. A systematic review and meta-analysis showed that guideline-adherent empirical therapy was associated with a relative risk reduction for mortality of 35%<sup>30</sup>. The reason for poor guideline compliance is uncertain and probably multifactorial, including local resistance patterns, ineffective guideline dissemination, and clinical uncertainty with fear of treatment failure. Our findings should trigger further detailed investigations at hospital and country level. The WHO AWaRe framework offers an attractive metric for LMIC in the absence of validated quality indicators for antibiotic appropriateness<sup>15,31,32</sup>, and includes a >60% national target of total antibiotic consumption in the Access category by 202333. However, a recent assessment of antibiotic consumption data from 76 countries in 2000-2015 found that the global per-capita consumption of Watch antibiotics increased by 90.9%, compared with an increase of 26.2% in Access antibiotics, with disproportionate increases in Watch antibiotic consumption in LMIC (165% compared with 27.9% in high-income countries)<sup>16</sup>. Although Indonesia national-level data have not been included in the AWaRE reports to date<sup>33</sup>, our survey found hospital consumption of Access antibiotics at 28% to be far below the 60% target, mostly driven by ceftriaxone and levofloxacin use for CAI and HAI. Although these findings could partially be explained by the national health insurance scheme which determines available antibiotics based on the national formulary<sup>34</sup>, they also highlight significant challenges for AMS.

 The limitations of this study are inherent to the cross-sectional "snap-shot" design. As we used a convenient hospital sample, data are not representative for all hospitals in Jakarta or Indonesia, urging caution in extrapolating the observed patterns. Antibiotic use patterns can be influenced by many factors, e.g. patient case mix, prevalence of different types of infections, AMR patterns, institutional factors, among others.

In conclusion, we observed high levels of parenteral, empiric use of broad-spectrum antibiotics in Indonesian hospitals, and inadequate performance on key quality indicators of prescribing. Despite important progress in AMS, supported by national policies<sup>9,10</sup> and guidelines<sup>35</sup>, the study findings highlighted the need to strengthen AMS to increase use of narrower-spectrum antibiotics through culture-guided targeted treatment and hospital guideline compliance. Further research is needed to understand the complex drivers of antibiotic prescribing, and to develop context-specific and feasible quality improvement strategies to strengthen existing AMS programmes.

384 Acknowledgements 385 We thank the management, research/medical committees and clinical staff of the participating 386 hospitals for their support, and Reinout van Crevel and Rogier van Doorn for useful feedback on 387 the manuscript. 388 389 **EXPLAIN** study group 390 Ralalicia Limato, Erni J. Nelwan, Manzilina Mudia, Helio Guterres, Enty Enty, Ifael Y. Mauleti, 391 Maria Mayasari, Iman Firmansyah, May Hizrani, Raph L. Hamers, Anis Karuniawati, Prof Taralan 392 Tambunan, Prof Amin Soebandrio, Prof Henri Verbrugh, Decy Subekti, Iqbal Elyazar, Mutia 393 Rahardjani, Fitria Wulandari, Prof Reinout van Crevel, Rogier van Doorn, Vu Thi Lan Huong, Nga 394 Do Ti Thuy, Sonia Lewycka, Prof Alex Broom. 395 396 **Funding** 397 This work was funded by the Wellcome Trust, UK (106680/Z/14/Z) 398 399 **Transparency declarations** 400 Conflicts of interest: The authors declare no competing interests. 401 Author contributions: EJN and RLH conceived the idea for the study and are the principal 402 investigators. RLH obtained the funding. RL, EJN and RLH designed the study protocol. MM, HG, 403 EE, IYM, MM, IF, and MH collected and verified the data, overseen by RL. RL and MM curated the 404 database, did the analysis and had full access to all study data, supervised by EJN and RLH. RL, 405 MM and RLH drafted the paper. All authors critically revised the manuscript and all authors gave 406 approval for the final version to be published.

#### References

- 408 1. O'Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. AMR
- 409 Rev Pap 2014.

- 2. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: An
- analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14: 742–50. Available at:
- 412 http://dx.doi.org/10.1016/S1473-3099(14)70780-7.
- 413 3. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and
- 414 association with resistance: a cross-national database study. *Lancet* 2005; **365**: 579–87.
- 4. Klein EY, Van Boeckel TP, Martinez EM, et al. Global increase and geographic convergence in
- antibiotic consumption between 2000 and 2015. Proc Natl Acad Sci U S A 2018; 115: E3463–70.
- 5. World Health Organization (WHO). Global Action Plan on Antimicrobial Resistance. 2015.
- 418 6. Zellweger M, Carrique-mas J, Limmathurotsakul D, Day NPJ, Thwaites GE. A current
- 419 perspective on antimicrobial resistance in Southeast Asia. J Antimicrob Chemother 2017; 72:
- 420 2963–72. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890732/pdf/dkx260.pdf.
- 7. Coker RJ, Hunter BM, Rudge JW, Liverani M, Hanvoravongchai P. Emerging infectious
- diseases in southeast Asia: Regional challenges to control. *Lancet* 2011; **377**: 599–609. Available
- 423 at: http://dx.doi.org/10.1016/S0140-6736(10)62004-1.
- 8. Parathon H, Kuntaman K, Widiastoety TH, et al. Progress towards antimicrobial resistance
- 425 containment and control in Indonesia. BMJ 2017; **358**: 31–5.
- 9. Ministry of Health Republic of Indonesia. Minister of Health Republic of Indonesia Policy No. 8
- 427 Year 2015. 2015.
- 428 10. Hospital Accrediation Committee. Standard Hospital Accreditation 1st Edition. Komisi
- 429 Akreditasi Rumah Sakit 2017: 1–421. Available at: http://akreditasi.kars.or.id/downloads/RS-
- 430 Template.xls.
- 431 11. World Health Organization (WHO). WHO Methodology for Point Prevalence Survey on
- 432 Antibiotic Use in Hospitals Version 1.1. 2018. Available at:
- 433 https://apps.who.int/iris/bitstream/handle/10665/280063/WHO-EMP-IAU-2018.01-eng.pdf?ua=1.
- 434 12. Versporten A, Bielicki J, Drapier N, et al. The worldwide antibiotic resistance and prescribing in
- european children (ARPEC) point prevalence survey: Developing hospital-quality indicators of
- antibiotic prescribing for children. *J Antimicrob Chemother* 2016; **71**: 1106–17.
- 437 13. Versporten A, Zarb P, Caniaux I, et al. Antimicrobial consumption and resistance in adult
- 438 hospital inpatients in 53 countries: results of an internet-based global point prevalence survey.
- 439 Lancet Glob Heal 2018; 6: e619–29. Available at: http://dx.doi.org/10.1016/%0AS2214-
- 440 109X(18)30186-4.
- 14. Saleem Z, Hassali MA, Godman B, et al. Point prevalence surveys of antimicrobial use: a
- systematic review and the implications. Expert Rev Anti Infect Ther 2020; 0: 1. Available at:
- 443 https://doi.org/10.1080/14787210.2020.1767593.
- 15. World Health Organization (WHO). WHO releases the 2019 AWaRe Classification Antibiotics.

- 445 2019. Available at:
- 446 https://www.who.int/medicines/news/2019/WHO releases2019AWaRe classification antibiotics/e
- 447 n/.
- 16. Klein EY, Milkowska-Shibata M, Tseng KK, et al. Assessment of WHO antibiotic consumption
- and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data. Lancet
- 450 Infect Dis 2020; **3099**. Available at: http://dx.doi.org/10.1016/S1473-3099(20)30332-7.
- 451 17. Goossens H. Global Point Prevalence Survey of Antimicrobial Consumption and Resistance
- 452 (2018 Global-PPS): Protocol. 2018.
- 453 18. Thamlikitkul V, Rattanaumpawan P, Sirijatuphat R, Wangchinda W. Integrated one-day
- 454 surveillance of antimicrobial use, antimicrobial consumption, antimicrobial resistance, healthcare-
- associated infection, and antimicrobial resistance burden among hospitalized patients in Thailand.
- 456 *J Infect* 2020; **81**: 98–106. Available at: https://doi.org/10.1016/j.jinf.2020.04.040.
- 457 19. Singh SK, Sengupta S, Antony R, et al. Variations in antibiotic use across India: multi-centre
- 458 study through Global Point Prevalence survey. *J Hosp Infect* 2019; **103**: 280–3. Available at:
- 459 https://doi.org/10.1016/j.jhin.2019.05.014.
- 460 20. Hadi U, Kuntaman K, Qiptiyah M, Paraton H. Problem of Antibiotic Use and Antimicrobial
- Resistance in Indonesia: Are We Really Making Progress? Indones J Trop Infect Dis 2013; 4: 5.
- 21. Saleem Z, Hassali MA, Versporten A, et al. A multicenter point prevalence survey of antibiotic
- use in Punjab, Pakistan: findings and implications. Expert Rev Anti Infect Ther 2019; 17: 285–93.
- 464 Available at: https://doi.org/10.1080/14787210.2019.1581063.
- 465 22. Xie D shuang, Xiang L li, Li R, Hu Q, Luo Q qin, Xiong W. A multicenter point-prevalence
- survey of antibiotic use in 13 Chinese hospitals. J Infect Public Health 2015; 8: 55–61. Available
- at: http://dx.doi.org/10.1016/j.jiph.2014.07.001.
- 23. Thu TA, Rahman M, Coffin S, Harun-Or-Rashid M, Sakamoto J, Hung NV. Antibiotic use in
- Vietnamese hospitals: A multicenter point-prevalence study. Am J Infect Control 2012; 40: 840–4.
- 470 24. Dahesihdewi A, Sugiani AK, Parwati I. Data Surveilans Mikroba Dan Kepekaannya Terhadap
- 471 Antibiotik Berdasarkan Tipe Rumah Sakit Di Indonesia Tahun 2017. Jakarta, Indonesia; 2018.
- 472 25. European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-
- 473 associated infections and antimicrobial use in European acute care hospitals. Stockholm; 2013.
- 474 26. World Health Organization (WHO). Global guidelines on the prevention of surgical site
- *infection.* Geneva, Switzeland; 2018. Available at: http://www.who.int/gpsc/ssi-prevention-
- 476 guidelines/en/#.WB6CWivkT70.mendeley.
- 477 27. van den Bosch CMA, Hulscher MEJL, Natsch S, Wille J, Prins JM, Geerlings SE. Applicability
- 478 of generic quality indicators for appropriate antibiotic use in daily hospital practice: a cross-
- sectional point-prevalence multicenter study. *Clin Microbiol Infect* 2016; **22**: 888.e1-888.e9.
- 480 Available at: http://dx.doi.org/10.1016/j.cmi.2016.07.011.
- 481 28. Malcolm W, Nathwani D, Davey P, et al. From intermittent antibiotic point prevalence surveys
- 482 to quality improvement: Experience in Scottish hospitals. Antimicrob Resist Infect Control 2013; 2:

- 483 1–9.
- 29. Zarb P, Amadeo B, Muller A, et al. Identification of targets for quality improvement in
- antimicrobial prescribing: The web-based ESAC point prevalence survey 2009. *J Antimicrob*
- 486 Chemother 2011; **66**: 443–9.
- 487 30. Schuts EC, Hulscher MEJL, Mouton JW, et al. Current evidence on hospital antimicrobial
- 488 stewardship objectives: A systematic review and meta-analysis. Lancet Infect Dis 2016; 16: 847–
- 489 56. Available at: http://dx.doi.org/10.1016/S1473-3099(16)00065-7.
- 490 31. World Health Organization (WHO). Adopt AWaRe: Handle antibiotics with care. 2019.
- 491 Available at: https://adoptaware.org/.
- 492 32. Sharland M, Pulcini C, Harbarth S, et al. Classifying antibiotics in the WHO Essential
- 493 Medicines List for optimal use—be AWaRe. Lancet Infect Dis 2018; 18: 18–20. Available at:
- 494 http://dx.doi.org/10.1016/S1473-3099(17)30724-7.
- 495 33. World Health Organization (WHO). WHO report on surveillance of antibiotic consumption:
- 496 2016-2018 early implementation. Geneva, Switzeland; 2018. Available at:
- 497 https://apps.who.int/iris/bitstream/handle/10665/277359/9789241514880-eng.pdf.
- 498 34. Yuniarti E, Prabandari YS, Kristin E, Suryawati S. Rationing for medicines by health care
- 499 providers in Indonesia National Health Insurance System at hospital setting: A qualitative study. J
- 500 Pharm Policy Pract 2019; **12**: 1–11.
- 35. Ministry of Health Republic of Indonesia. Minister of Health Policy on General Guideline of
- 502 Antibiotic Use. 2011. Available at:
- 503 https://www.google.co.id/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=0a
- 504 hUKEwjEh8GnxurXAhVMNl8KHVx6DooQFggzMAE&url=http%3A%2F%2Fjdih.pom.go.id%2Fsho
- 505 wpdf.php%3Fu%3DcTcp0eStSVTlmXC7Av%252BxK5RLEij8it%252Fhu%252FnLTo3HCOs%253
- 506 D&usg=AOvVaw34g7pV.

**Table 1. Hospital characteristics** 

	Total	Hospital 1	Hospital 2	Hospital 3	Hospital 4	Hospital 5	Hospital 6
Level of health service	-	Secondary	Tertiary	Secondary	Secondary	Tertiary	Secondary
Sector	-	Private	Public	Private	Public	Public	Private
Teaching hospital	-	Yes	Yes	Yes	No	Yes	No
National health insurance scheme <sup>a</sup>	-	No	Yes	Yes	Yes	Yes	No
Hospital antibiotic guidelines	-	No	Yes	Yes	Yes	Yes	Yes
Inpatient wards <sup>b</sup>	238	19	74	30	14	79	22
Medical wards	87	4	27	15	6	30	5
Surgical wards	31	0	17	2	0	11	1
Mixed medical-surgical wards <sup>c</sup>	95	12	19	10	7	32	15
Intensive care units	25	3	11	3	1	6	1
Adult	123	8	55	13	2	39	6
Paediatric and/or neonatal	51	5	12	6	3	21	4
Mixed adult-neonatal-paediatric <sup>d</sup>	64	6	7	11	9	19	12
Inpatient beds	2358	159	767	300	145	853	134
Admitted patients	1602 (67.9)	100 (62.9)	562 (73.3)	198 (66.0)	66 (45.5)	625 (73.3)	51 (38.1)
Admitted patients on ≥1 antimicrobials	993 (62.0)	75 (75.0)	368 (65.5)	106 (53.5)	52 (78.8)	359 (57.4)	33 (64.7)
Medical ward	310 (31.2)	47 (62.7)	102 (27.7)	45 (42.5)	14 (26.9)	95 (26.5)	7 (21.2)
Surgical ward	184 (18.5)	0 (0.0)	87 (23.6)	24 (22.6)	0 (0.0)	73 (20.3)	0 (0.0)
Mixed medical-surgical ward <sup>c</sup>	401 (40.4)	23 (30.7)	135 (36.7)	37 (34.9)	35 (67.3)	147 (40.9)	24 (72.7)
Intensive care unit	98 (9.9)	5 (6.7)	44 (12.0)	0 (0.0)	3 (5.8)	44 (12.3)	2 (6.1)
Adult ward	727 (73.2)	31 (41.3)	298 (81.0)	92 (86.8)	43 (82.7)	230 (64.0)	33 (100)
Paediatric ward	163 (16.4)	13 (17.4)	58 (15.7)	8 (7.5)	3 (5.7)	81 (22.6)	0 (0.0)
Mixed adult-neonatal-paediatric ward <sup>d</sup>	103 (10.4)	31 (41.3)	12 (3.3)	6 (5.7)	6 (11.6)	48 (13.4)	0 (0.0)
Data shown reflect the hospital situation or <sup>a</sup> National health insurance scheme, <i>Jamin</i> <sup>b</sup> Includes all inpatients wards in the hospit <sup>c</sup> Wards that can admit both medical and so <sup>d</sup> Wards that can admit both adult, paediatr	an Kesehatan Na al. Some wards ha urgical patients.	s <i>ional (JKN).</i> ave been further su	-		e specified.		

Table 2. Characteristics of patients receiving ≥1 antimicrobials

	Total (n=993)	Hospital 1 (n=75)	Hospital 2 (n=368)	Hospital 3 (n=106)	Hospital 4 (n=52)	Hospital 5 (n=359)	Hospital 6 (n=33)
Female	497 (50.1)	41 (54.7)	186 (50.5)	61 (57.5)	22 (42.3)	175 (48.7)	12 (36.4)
Age (median, IQR) <sup>a</sup>	43 (22-58.5)	29 (20-55)	47 (25-60)	52 (33-66)	39.5 (28-59)	37 (8-53)	51 (28.5-65)
<1 month (neonates)	45 (4.5)	2 (2.7)	17 (4.6)	2 (1.9)	1 (1.9)	23 (6.4)	0 (0.0)
1-23 months	63 (6.3)	3 (4.0)	20 (5.4)	2 (1.9)	1 (1.9)	37 (10.3)	0 (0.0)
2-17 years	103 (10.4)	12 (16.0)	24 (6.5)	6 (5.7)	4 (7.7)	57 (15.9)	0 (0.0)
18-29 years	131 (13.2)	21 (28.0)	47 (12.8)	7 (6.6)	8 (15.4)	39 (10.9)	9 (27.3)
30-39 years	112 (11.3)	9 (12.0)	35 (9.5)	24 (22.6)	12 (23.1)	30 (8.4)	2 (6.1)
40-49 years	145 (14.6)	7 (9.3)	55 (14.9)	7 (6.6)	8 (15.4)	63 (17.5)	5 (15.2)
≥50 years	394 (39.7)	21 (28.0)	170 (46.2)	58 (54.7)	18 (34.6)	110 (30.6)	17 (51.5)
National health insurance holder <sup>b</sup>	743 (74.8)	0 (0.0)	329 (89.4)	24 (22.6)	50 (96.2)	340 (94.7)	0 (0.0)
Transfer from other hospital	145 (14.6)	2 (2.7)	70 (19.0)	2 (1.9)	10 (19.2)	57 (15.9)	4 (12.1)
Hospitalisation within 90 days <sup>c</sup>	299 (30.1)	12 (16.0)	86 (23.4)	20 (18.9)	20 (38.5)	151 (42.1)	10 (30.3)
Surgery in the past 90 days <sup>d</sup>	368 (37.1)	3 (4.0)	162 (44.0)	41 (38.7)	8 (15.4)	142 (39.6)	12 (36.4)
Catheter use							
Central vascular	132 (13.3)	4 (5.3)	35 (9.5)	12 (11.3)	1 (1.9)	73 (20.3)	7 (21.2)
Peripheral vascular	941 (94.8)	69 (92.0)	357 (97.0)	85 (80.2)	51 (98.1)	347 (96.7)	32 (97.0)
Urinary	363 (36.6)	9 (12.0)	183 (49.7)	35 (33.0)	9 (17.3)	119 (33.1)	8 (24.2)
Intubation	65 (6.5)	3 (4.0)	21 (5.7)	7 (6.6)	1 (1.9)	30 (8.4)	3 (9.1)
Documented comorbidity	486 (48.9)	11 (14.6)	209 (56.8)	40 (37.7)	41 (78.8)	174 (48.5)	14 (42.4)
Malnutrition	335 (33.7)	0 (0.0)	165 (44.8)	17 (16.0)	28 (53.8)	121 (33.7)	4 (12.1)
Diabetes mellitus	161 (16.2)	8 (10.7)	68 (18.5)	24 (22.6)	14 (26.9)	39 (10.9)	8 (24.2)
Tuberculosis	120 (12.1)	3 (4.0)	37 (10.1)	7 (6.6)	24 (46.2)	44 (12.3)	5 (15.2)
HIV	44 (4.4)	3 (4.0)	10 (2.7)	2 (1.9)	13 (25.0)	16 (4.5)	0 (0.0)
HIV on antiretroviral treatment	27 (2.7)	3 (4.0)	4 (1.1)	2 (1.9)	8 (15.4)	10 (2.8)	0 (0.0)
Chronic obstructive pulmonary disease	11 (1.1)	0 (0.0)	7 (1.9)	0 (0.0)	3 (5.8)	1 (0.3)	0 (0.0)
McCabe score <sup>e</sup>							
Rapidly fatal	29 (2.9)	3 (4.0)	8 (2.2)	2 (1.9)	0 (0.0)	15 (4.2)	1 (3.0)
Ultimately fatal	217 (21.9)	3 (4.0)	89 (24.2)	32 (30.2)	2 (3.8)	84 (23.4)	7 (21.2)
Non-fatal	746 (75.1)	69 (92.0)	270 (73.4)	72 (67.9)	50 (96.2)	260 (72.4)	25 (75.8)
Unknown	1 (0.1)	0 (0.0)	1 (0.1)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Prescribed antimicrobial drugs	1,666	114	630	158	98	622	44
Median (range) per patient	1 (1-12)	1 (1-12)	1 (1-9)	1 (1-7)	1 (1-6)	1 (1-10)	1 (1-4)
1	602 (60.6)	58 (77.3)	204 (55.4)	74 (69.8)	32 (61.5)	209 (58.2)	25 (75.8)
2	254 (25.6)	11 (14.7)	108 (29.3)	22 (20.8)	8 (15.4)	99 (27.6)	6 (18.2)
≥3	137 (13.8)	6 (8.0)	56 (15.2)	10 (9.4)	12 (23.1)	51 (14.2)	2 (6.1)

Data shown reflect the hospital situation on the survey day, and are expressed as number (percentage), unless otherwise specified

<sup>&</sup>lt;sup>a</sup> Median (IQR) age was 47 (28-60) years for adults, 7 (2-11) months for children <2 years, and 8 (3-14) days for neonates

<sup>&</sup>lt;sup>b</sup> Jaminan Kesehatan Nasional (JKN); Unknown for 4 (0.4%) participants.

<sup>&</sup>lt;sup>c</sup> Before the current admission, the patient has been hospitalized within 90 days before the survey date.

<sup>&</sup>lt;sup>d</sup> The patient underwent surgery in the past 90 days before the survey date, including surgery prior to and during the current admission

<sup>&</sup>lt;sup>e</sup> McCabe score is a simple subjective method to assess underlying illness severity and classify patients according to a prognosis of rapidly fatal (<1 year), ultimately fatal (1–4 years) and non-fatal (>5 years) (Reilly et al. J Infect Prev 2016:17(3):127–129).

Table 3. Most common diagnosis for systemic antibiotic use

Diagnosis	Total (n=1,273)
Pneumonia or lower respiratory tract infection	353 (27.7)
Skin and soft tissue infection <sup>a</sup>	106 (8.3)
Prophylaxis for gastrointestinal infections <sup>b</sup>	101 (7.9)
Gastrointestinal infection	69 (5.4)
Prophylaxis for bone and joint infection <sup>c</sup>	58 (4.6)
Prophylaxis for obstetrics or gynaecological infection	58 (4.6)
Intra-abdominal infection <sup>d</sup>	57 (4.5)
Unknown reason	47 (3.7)
Sepsis	46 (3.6)
Prophylaxis for urinary tract infection (surgery or recurrent infection)	42 (3.3)
Other diagnosis <sup>e</sup>	35 (2.7)
Ear, nose, throat infection <sup>f</sup>	30 (2.4)
Upper urinary tract infection <sup>g</sup>	29 (2.3)
Central nervous system infection	26 (2.0)
Medical prophylaxis for new-born risk factors	25 (2.0)

The table lists the 15 most common reasons to prescribe at least one antibiotic for systemic use (J01). Data are expressed as numbers (percentage) and ranked by frequency. Patients recorded with more than one diagnosis were counted by number of diagnoses. Diagnosis were coded based on the GLOBAL-PPS 2018 Diagnostic Code List. The full list of diagnosis is shown in Table S6.

<sup>&</sup>lt;sup>a</sup> Including cellulitis, wound including surgical site infections, deep soft tissue not involving bone (e.g. infected pressure or diabetic ulcers, abscess).

Including prophylaxis for surgery of the gastrointestinal tract, liver, or biliary tree, and prophylaxis in patients with neutropenia or hepatic failure.

<sup>&</sup>lt;sup>c</sup> Including prophylaxis for surgical site infections, for plastic or orthopaedic surgery (bone or joint).

d Including hepatobiliary, intra-abdominal abscess, etc.

<sup>&</sup>lt;sup>e</sup> Antibiotic prescribed with documentation for which there is no above diagnosis group.

f Including mouth, sinuses, larynx.

<sup>&</sup>lt;sup>g</sup> Including catheter related urinary tract infection, pyelonephritis.

Table 4. Quality indicators for antibiotic prescribing, by indication

Quality indicators	Total (n=1,273)		Т	herapeutic use (n=777)		P	rophylactic use (n=410)	Other indication <sup>a</sup> (n=27)	Unknown indication (n=59)
		CAI empirical (n=498)	CAI targeted (n=44)	HAI empirical (n=172)	HAI targeted (n=63)	Medical prophylaxis (n=122)	Surgical prophylaxis (n=288)		
Reason documented	808 (63.5)	321 (64.5)	35 (79.5)	145 (84.3)	45 (71.4)	58 (47.5)	172 (59.7)	21 (77.8)	11 (18.6)
Stop/review date documented	194 (15.2)	69 (13.9)	7 (15.9)	43 (25.0)	18 (28.6)	15 (12.3)	38 (13.2)	2 (7.4)	2 (3.4)
Treatment duration documented	125 (9.8)	35 (7.0)	5 (11.4)	31 (18.0)	12 (19.0)	3 (2.5)	35 (12.2)	0 (0.0)	4 (6.8)
Guideline compliance									
Yes	478 (37.5)	223 (44.8)	17 (38.6)	79 (45.9)	33 (52.4)	23 (18.9)	82 (28.5)	21 (77.8)	0 (0.0)
No	378 (29.7)	136 (27.3)	16 (36.4)	70 (40.7)	20 (31.7)	6 (4.9)	124 (43.1)	6 (22.2)	0 (0.0)
Not assessable <sup>b</sup>	358 (28.1)	139 (27.9)	11 (25.0)	23 (13.4)	10 (15.9)	93 (76.2)	82 (28.5)	0 (0.0)	0 (0.0)
Indication unknown	59 (4.6)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	59 (100.0)
Route of administration									
Parenteral (IV)	1,084 (85.2)	444 (89.2)	42 (95.5)	150 (87.2)	58 (92.1)	92 (75.4)	237 (82.3)	10 (37.0)	51 (86.4)
Oral	183 (14.38)	52 (10.44)	2 (4.55)	22 (12.79)	5 (7.94)	30 (24.59)	51 (17.71)	13 (48.15)	8 (13.56)
IV-oral switch	48 (26.2)	6 (11.5)	1 (50.0)	9 (40.9)	1 (20.0)	1 (3.3)	28 (54.9)	0 (0.0)	2 (25.0)
Other	6 (0.47)	2 (0.40)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	4 (14.81)	0 (0.00)
Culture sample taken <sup>c</sup>	344 (44.3)	125 (25.1)	44 (100)	112 (65.1)	63 (100)	-	-	-	-

Abbreviations: CAI, community acquired infection; HAI, hospital acquired infection; IV, intravenous

<sup>&</sup>lt;sup>a</sup> Other indication included antibiotics prescribed for neurotoxoplasmosis, pulmonary tuberculosis, and as motility agent. <sup>b</sup> Hospital antibiotic guidelines were not available to assess compliance.

<sup>&</sup>lt;sup>c</sup> Only applicable to therapeutic use.




Figure 1. Systemic antibiotic use by antibiotic class, by indication




Figure 2. Systemic antibiotic use by AWaRe classification

Total antibiotic use		Therapeutic use		Prophylactic use		Other Indication		Unknown Indication					
(n=1273) 90.6% DU		<b>CAI</b> (n=542) 89.7% DU		<b>HAI</b> (n=235) 89.4% DU		Medical prophylaxis (n=122) 92% DU		Surgical prophylaxis (n=288) 91.4% DU		- (n=27) 85.1% DU		(n=59) 83.2% DU	
Ceftriaxone	341 (26.8)	Ceftriaxone	178 (32.8)	Levofloxacin	44 (18.7)	Ceftriaxone	35 (28.7)	Ceftriaxone	76 (26.4)	Clindamycin	10 (37.0)	Ceftriaxone	29 (49.2)
Levofloxacin	136 (10.7)	Levofloxacin	73 (13.5)	Meropenem	32 (13.6)	Cotrimoxazole	21 (17.2)	Cefixime	33 (11.5)	Streptomycin	10 (37.0)	Cefotaxime	7 (11.9)
Metronidazole	90 (7.1)	Metronidazole	44 (8.1)	Ceftriaxone	23 (9.8)	Gentamicin	13 (10.7)	Cefoperazone	32 (11.1)	Levofloxacin	3 (11.1)	Levofloxacin	5 (8.5)
Meropenem	82 (6.4)	Meropenem	42 (7.7)	Amikacin	15 (6.4)	Cefotaxime	10 (8.2)	Metronidazole	28 (9.7)			Metronidazole	2 (3.4)
Cefotaxime	71 (5.6)	Ampicillin β-LI	29 (5.4)	Metronidazole	14 (6.0)	Ampicillin	9 (7.4)	Cefazolin	18 (6.2)			Meropenem	2 (3.4)
Cefoperazone	52 (4.1)	Cefotaxime	27 (5.0)	Ceftazidime	14 (6.0)	Cefoperazone βLI	6 (4.9)	Amoxicillin βLI	16 (5.6)			Gentamicin	2 (3.4)
Cefixime	51 (4.0)	Gentamicin	17 (3.1)	Cefotaxime	12 (5.1)	Cefoperazone	4 (3.3)	Cefotaxime	14 (4.9)			Amoxicillin	2 (3.4)
Ampicillin βLI	44 (3.5)	Cefixime	12 (2.2)	Ciprofloxacin	9 (3.8)	Ampicillin βLI	4 (3.3)	Levofloxacin	8 (2.8)				
Gentamicin	42 (3.3)	Cefoperazone	11 (2.0)	Cefoperazone βLI	6 (2.6)	Amoxicillin	4 (3.3)	Gentamicin	7 (2.4)				
Amikacin	32 (2.5)	Amikacin	10 (1.8)	Azithromycin	6 (2.6)	Levofloxacin	3 (2.5)	Cefoperazone βLI	6 (2.1)				
Amoxicillin βLI	31 (2.4)	Cefoperazone βLI	9 (1.7)	Tigecycline	6 (2.6)	Erythromycin	3 (2.5)	Amikacin	6 (2.1)				
Cefoperazone βLI	28 (2.2)	Ciprofloxacin	9 (1.7)	Cefoperazone	5 (2.1)			Fosfomycin	6 (2.1)				
Cotrimoxazole	28 (2.2)	Azithromycin	9 (1.7)	Ampicillin βLI	5 (2.1)			Ampicillin βLI	5 (1.7)				
Ceftazidime	21 (1.6)	Amoxicillin βLI	8 (1.5)	Amoxicillin βLI	5 (2.1)			Ampicillin	4 (1.4)				
Ciprofloxacin	21 (1.6)	Moxifloxacin	8 (1.5)	Fosfomycin	5 (2.1)			Cefadroxil	4 (1.4)				
Cefazolin	18 (1.5)			Piperacillin βLI	5 (2.1)								
Ampicillin	17 (1.3)			Doripenem	4 (1.7)								
Amoxicillin	16 (1.3)												
Azithromycin	16 (1.3)												
Clindamycin	16 (1.3)												
Access antibiotic	group	Watch antibiotic	group	Reserve antibiotic	group	Unclassified ant	ibiotic group	)					

Data are expressed as numbers (percentage). Antibacterial prescriptions for systemic use (J01) were included.

Abbreviations: DU 90%, the number of drugs which account for 90% of the prescriptions; CAI, community acquired infection; HAI, hospital acquired infection; BLI, and beta lactamase inhibitor

Figure 3. Systemic antibiotic use by indication based on AWaRe classification